Raymond James Financial Inc. acquired a new stake in STERIS plc (NYSE:STE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,089,642 shares of the medical equipment provider's stock, valued at approximately $223,987,000. Raymond James Financial Inc. owned approximately 1.10% of STERIS at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of STE. Ashton Thomas Securities LLC bought a new position in STERIS in the third quarter valued at approximately $25,000. Human Investing LLC bought a new position in shares of STERIS in the fourth quarter valued at $31,000. Anfield Capital Management LLC increased its holdings in STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after buying an additional 91 shares during the last quarter. Central Pacific Bank Trust Division raised its position in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC raised its position in STERIS by 182.7% during the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 137 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
STERIS Stock Performance
NYSE:STE traded down $1.25 during mid-day trading on Monday, reaching $231.49. 668,637 shares of the company's stock were exchanged, compared to its average volume of 522,987. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The firm has a market capitalization of $22.74 billion, a PE ratio of 49.15 and a beta of 0.92. STERIS plc has a one year low of $197.82 and a one year high of $248.24. The business's fifty day simple moving average is $216.96 and its two-hundred day simple moving average is $222.70.
STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.
STERIS Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.98%. STERIS's payout ratio is 48.41%.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on STE. Stephens reaffirmed an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. Piper Sandler lifted their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, JMP Securities restated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, STERIS currently has an average rating of "Moderate Buy" and an average price target of $258.75.
Check Out Our Latest Stock Analysis on STERIS
STERIS Company Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
